Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Pemetrexed and Gemcitabine in Advanced NSCLC
NCT00071136Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Dec 2003; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00071136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071136.